Overall, revenues were up 8 percent. In the diagnostics segment, molecular product sales were driven primarily by continued strength across Aptima women's health products.
Alere received FDA 510(k) clearances for four tests, including those for influenza A and B, strep A, and RNA-based respiratory syncytial virus.
The firm noted that the premarket approval means that the three major viral load assays that most laboratories run for patients are now available on a single system.
The firm has said that it intends to use the net proceeds and available cash to redeem its outstanding 5.25 percent senior notes due in 2022 in the amount of $1 billion.
The firm intends to use the net proceeds and available cash to redeem its outstanding 5.25 percent senior notes due 2022 in the amount of $1 billion.
With WHO prequalification, global health organizations can consider the Aptima HIV-1 Quant Dx for public-sector procurement in resource-limited countries.
Among the diagnostic firms presenting at the conference on Tuesday were lab giant LabCorp, diversified medical products firm Hologic, and MDx startups, such as Adaptive Biotechnologies.
For its first fiscal quarter, the firm's diagnostics business revenues are expected to drop to $285 million from $325 million in the prior-year quarter.
The investment bank noted that Hologic could be the "biggest beneficiary from tax reform" in its coverage with a potential 8 percent benefit to earnings per share.
The investment bank's upgrade is based on an expectation of resilient revenue growth for the firm's molecular diagnostics business, among other growth drivers.